MOHINDER PARTAP: Open Payments
NPI 1235137035 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,599 in 142 payments from 21 companies in 2025. Trend: 2023 $1,374 · 2024 $1,792 · 2025 $2,599
Food & beverage: $2,595Education: $4
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $446 |
| Neurocrine BioSciences, Inc. | 19 | $444 |
| Vanda Pharmaceuticals Inc. | 9 | $330 |
| Alkermes, Inc. | 20 | $290 |
| E.R. Squibb & Sons, L.L.C. | 17 | $235 |
| ABBVIE INC. | 13 | $201 |
| Otsuka America Pharmaceutical, Inc. | 11 | $144 |
| Lundbeck LLC | 5 | $107 |
| UCB, Inc. | 2 | $52 |
| Neos Therapeutics, LP | 3 | $50 |
Products named: CAPLYTA, INGREZZA, FANAPT, ARISTADA, COBENFY, VRAYLAR, REXULTI, Adzenys XR-ODT.
Industry payments across MO — which companies pay providers there.
